$3.54
-0.0700 (-1.94%)
At Close: Jun 22, 2026
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting
01:00pm, Sunday, 01'st May 2022 GlobeNewswire Inc.
-- Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up ---- All Patients with
-- Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up -- -- All Patients wit
Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
07:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
04:50pm, Wednesday, 27'th Apr 2022
Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AI Pharma Startup METiS Raises $150 Million. IPO In Sight?
03:45pm, Tuesday, 12'th Apr 2022 Benzinga
Key takeaways:
METiS Pharmaceuticals has completed five funding rounds since its establishment in January 2020, including the latest two worth $150 million
The company was incubated by AI pharmaceuti
Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting
04:01pm, Monday, 04'th Apr 2022
ARLINGTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2022
02:22pm, Wednesday, 30'th Mar 2022 Benzinga
Upgrades
For Cal-Maine Foods Inc (NASDAQ:CALM), Consumer Edge Research upgraded the previous rating of Equal-Weight to Overweight. For the third quarter, Cal-Maine Foods had an EPS of $0.81, compared
Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates
12:15pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Kala Pharma (KALA) delivered earnings and revenue surprises of -58.14% and 45.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2021 Results - Earnings Call Transcript
12:10pm, Tuesday, 29'th Mar 2022
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2021 Results - Earnings Call Transcript
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
11:41am, Tuesday, 29'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug
Pfizer, Inc.
Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates
09:47am, Tuesday, 29'th Mar 2022
Kala Pharma (KALA) delivered earnings and revenue surprises of -58.14% and 45.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call
08:00am, Wednesday, 23'rd Mar 2022
ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization
Thinking about buying stock in Volt Information Sciences, Arcadia Biosciences, Deutsche Bank, Biofrontera, or Kala Pharmaceuticals?
12:30pm, Monday, 14'th Mar 2022 Benzinga
NEW YORK , March 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VOLT, RKDA, DB, BFRI, and KALA. … Full story available on Benzinga.com
95 Biggest Movers From Friday
08:52am, Monday, 14'th Mar 2022 Benzinga
Gainers Marygold Companies (NYSE: MGLD ) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF ) gained 49.3% to close at $9.51. Guardforce AI Co., Limited (NASDAQ: GFAI ) jumped 45% to settle at $0.7796 after the company agreed to acquire Shenzhen Keweien and Guangzhou Kewei for $10 million. Clearside Biomedical, Inc. (NASDAQ: CLSD ) rose 42.6% to settle at $1.9250 after the company reported better-than-expected Q4 results. Excellon Resources Inc. (NYSE: EXN ) rose 40.8% to close at $1.38 after jumping around 13% on Thursday. Solid Biosciences Inc. (NASDAQ: SLDB ) jumped 37.4% to settle at $1.06. Altamira Therapeutics Ltd. (NASDAQ: CYTO ) shares gained 36.7% to settle at $0.9449. Altamira Therapeutics reported in vitro efficacy data for bentrio nasal spray in protecting against Sars-CoV-2 omicron variant. 4D pharma plc (NASDAQ: LBPS ) shares surged 35.3% to settle at $3.99. Kala Pharmaceuticals, Inc. (NASDAQ: KALA ) gained 33.1% to close at $1.69.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb''s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
09:37pm, Sunday, 13'th Mar 2022 Benzinga
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week. Kala Pharmaceuticals, Inc. (NASDAQ: KALA ) was among the biggest gainers of the week. The stock moved out of penny stock territory after the company announced UnitedHealth Incorporated (NYSE: UNH ) added Eysuvis 0.25% as a covered brand on its commercial formularies, effective March 2022. China-based biopharma companies Zai Lab Ltd. (NASDAQ: ZLAB ), BeiGene Ltd. (NASDAQ: BGNE ) and Hutchmed China Ltd (NASDAQ: HCM ) came under selling pressure after the SEC included these companies in the list of companies facing delisting threat. Here are the key catalysts that could move stocks in the unfolding week: Conferences World Sleep Congress, or WSC, 2022: March 11-16, in Rome, Italy Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (hybrid event): March 13-16 Roth 34th Annual Healthcare Conference: March 14 Oppenheimer Virtual Annual Healthcare Conference: March 15-16 Barclays Global Healthcare Conference: March 15-17, in Miami, Florida AD/PD 2022: International Conference On Alzheimer''s And Parkinson''s Diseases And Related Neurological Disorders: March 15-22, in Barcelona, Spain 1st Annual Needham Virtual Neuroscience Forum: March 16 Guggenheim Virtual Healthcare Talks - Targeted Protein Degradation Day: March 16 American Society for Clinical Pharmacology & Therapeutics, ASCPT, Annual Meeting: March 16-18 Society of American Gastrointestinal And Endoscopic Surgeons, or SAGES, 2022 Annual Meeting: March 16-19, in Denver, Colorado American Pain Society, or APS, Annual Scientific Meeting: March 17-20, in Scottsdale, Arizona Society of Gynecologic Oncology, or SGO, Annual Meeting on Women''s Cancer: March 19-22, in Phoenix, Arizona European Group for Blood and Marrow Transplantation, or EBMT, Annual Congress: March 19-23, in Prague, Czech Republic PDUFA Dates The Food and Drug …
Sign In
Buy KALA